1. Introduction
===============

The esophageal cancer is an extremely lethal disease worldwide; however, the prognosis of esophagus cancer in Iran is not as dismal as in other regions of the world ([@b1-epj-09-3756]--[@b3-epj-09-3756]). Although the prevalence of this neoplasm is relatively low globally, it is one of the most prevalent in Iran ([@b4-epj-09-3756]), ranking fifth and eighth among all types of cancers in women and men, respectively. Its incidence, however, varies according to its geographic distribution; i.e. it is more prevalent in the northern regions of Iran; Khorasan Razavi stands at third place for men and fourth place for women ([@b5-epj-09-3756]). Furthermore, Mashhad University of Medical Sciences is a referral center for cancer patients from adjacent provinces, namely Golestan, North Khorasan, etc. Currently, there is no definitive and efficient recommended standard for treatment of esophageal cancer, due to paucity of appropriately designed studies ([@b6-epj-09-3756]). Esophageal squamous cell carcinoma (SCC) is preceded by squamous dysplasia as a result of genetic divergence manifested by canonical oncogenes and tumor suppressor genes in somatic cells of the tumor. This genetic divergence consists of oncogenes such as epidermal growth factor receptor (EGFR) and cyclin D, and tumor suppressor genes such as P16INK4a and TP53 ([@b7-epj-09-3756]). Novel realizations of underlying molecular pathogenesis and biology of esophageal cancer have led to a resurgent interest in the study of targeted therapy in the field of this neoplasm ([@b8-epj-09-3756]). Early reports on adding vascular endothelial growth factor (VEGF) ligand-targeted agent and EGFR-targeted agent to chemoradiation, showed no improved outcomes. Therefore, currently available EGFR targeted therapies are not in use for esophageal cancers ([@b9-epj-09-3756]). However, ramucirumab, a human monoclonal antibody against VEGF2, has shown positive results in refractory esophageal cancer ([@b10-epj-09-3756]). To date, human epidermal growth factor receptor 2 (HER 2) targeted agent, trastuzumab, is the only targeted agent approved for treatment of metastatic HER 2 positive esophagogastric adenocarcinoma ([@b9-epj-09-3756]). Among different therapeutic targets identified, tumor specific antigens (TSAs) and tumor associated antigens (TAAs) are unique because of their exclusive expression in malignant tissues (disregarding testis) ([@b11-epj-09-3756]). CTAs, a group of TSAs/TAAs consisting of more than 100 immunogenic proteins including melanoma-associated antigen (MAGE), BAGE and GAGE families among others, are characterized by an unusual expression profile, mostly limited to the pre-meiotic germ cells of adult testis and cancer cells of diverse histological origin such as melanoma and carcinoma of breast and gastrointestinal tract ([@b12-epj-09-3756], [@b13-epj-09-3756]). MAGE1 expression in normal tissue is restricted to the testes, whilst being over-expressed in a number of human cancers. The MAGE family which is located on X-chromosome is frequently expressed in different carcinomas, and has diagnostic and therapeutic potentials. For example, MAGE is correlated with SCC histology in lung cancers ([@b14-epj-09-3756], [@b15-epj-09-3756]), with hormone-receptor--negative carcinomas in breast cancers ([@b16-epj-09-3756]), and with high-grade carcinomas in urothelial neoplasms ([@b17-epj-09-3756]). Several investigators proposed that MAGE1 plays a potential role in the carcinoma of the digestive tract, especially for the esophageal carcinoma. Haier et al reported that MAGE1 was expressed in half of esophageal SCCs; however, they did not find any prognostic value in this context ([@b18-epj-09-3756]). Chen et al and Liang et al showed that this antigen was expressed frequently in SCC of esophagus and was related to tumor progression ([@b19-epj-09-3756], [@b20-epj-09-3756]). These controversies still remain unresolved: whether MAGE1 cancer testis antigen has a specific clinicopathologic importance in high incidence areas such as Iran, has yet to be proved. In this study, we aimed to determine the expression of MAGE1 in Esophageal Squamous Cell Carcinoma and its relationship with clinicopathological factors in the north-east of Iran.

2. Material and Methods
=======================

2.1. Patients and Treatment
---------------------------

This was a cross-sectional study conducted on pretreatment endoscopic tissue specimens of 43 patients with non-metastatic esophageal SCC, admitted to Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, between 2011 and 2013. They had all undergone neoadjuvant chemoradiation (CRT) in a prospective clinical phase II trial, described by Anvari et al ([@b2-epj-09-3756]). In their study, 197 patients with stage Ib-IIIc esophageal SCC were recruited, 127 patients completed treatment, fourteen patients died due to surgical complications and two patients died of other causes. Of the 111 patients remaining, we had access to 43 patients' paraffin blocks of endoscopic SCC samples with detectable tumoral cells which were used in our study. CRT consisted of 40 gray radiotherapy and two courses of concurrent chemotherapy with cisplatin 20 mg/m2 for 4 days, plus 5-FU 700 mg/m2 24-h continuous infusion for 4 days in the 1st and 4th weeks of radiation therapy. Esophagectomy was performed 3--4 weeks after radiation therapy termination using the transhiatal technique with regional lymph node dissection. The mean number of resected lymph nodes was 4.05±2.79 (0--11).

2.2. Immunohistochemistry (IHC) and Scoring
-------------------------------------------

Immunohistochemical staining of MAGE1 was performed on pretreatment endoscopic specimens (before neoadjuvant CRT). For the detection of MAGE1 antigen, we used diluted NCL-MAGE1 monoclonal antibody (mAb), with the staining method described in detail below, according to Bolli's study ([@b21-epj-09-3756]). Tissue slides from paraffin embedded esophageal SCC samples were placed on Silane (3 aminopropyltriethoxysilane, A 3648, Sigma, St. Louis MO, USA). The deparaffinized slides were heated in an 800-W microwave oven at maximum power for 30 minutes (min), soaked in 10 mmol/l EDTA buffer (pH 6.0) for 5 min and then rinsed with a tris buffer solution (PBS, pH 7.2). The tris buffer solution was composed of saline, surfactant, and protein stabilizer 0.35% ProClinTM 950. To suppress endogenous peroxidase activity, slides were treated with H2O2. After additional rinsing with PBS, they were incubated for 20 min with a 1:10 dilution of normal rabbit serum (DakoX0902, Dako A/S) in a wet chamber at room temperature for 20 min to prevent non-specific binding of immunoglobulin. Dilutions were made of 1:50 and 1:100 of NCL-MAGE1 mAb with 1 cc of sterile distilled water. Slides were then treated with diluted mAbs at room temperature for 90 min. The Envision (Dako) system was used as a secondary detection tool and diaminobenzidine tetrahydrochloride served as a chromogen. The slides were counterstained with hematoxylin prior to our evaluation. Sections of normal human testis with intact spermiogenesis were used as positive controls for MAGE1 mAbs. Each dilution was performed on the same type of sample in order to retain the exact experimental conditions. [Figure 1](#f1-epj-09-3756){ref-type="fig"} shows IHC staining for MAGE1 in tumoral cells. MAGE1 staining results were scored according to Allred scoring system ([@b22-epj-09-3756]), consisting of four categories based on microscopic observations including strongly positive, moderately positive, weakly positive and no staining. All results of IHC were reported based on the mutual assessment of two expert pathologists. We graded pathologic response on a 0--3 scale as follows; complete response (Grade 0) as no cancer cells, moderate response (Grade 1) as single cells or small groups of cancer cells, minimal response (Grade 2) as residual cancer cells outgrowth by fibrosis, and poor response (Grade 3) as minimal or no treatment effect. Then they were categorized into two general subgroups: favorable response (grade 0 and 1) and unfavorable response (grade 2 and 3).

2.3. Statistical Analysis
-------------------------

The sample size used in the study (n=43) was determined based on Haier et al. ([@b18-epj-09-3756]) using n=Z21-α/2 P(1-P)/d2 while the confidence interval, estimated proportion, and desired precision was considered 90%, 50%, and d/4, respectively. The association between immunohistochemical findings and different clinicopathological parameters was evaluated by chi-square test, T-test, and Pearson test; p \<0.05 was considered significant. For all statistical analyses, the computer program SPSS 16 (SPSS Inc. Chicago, Illinois, USA) was used.

2.4. Research Ethics
--------------------

This study was approved by the Ethics Committee of Mashhad University of Medical Sciences after its scientific approval by the Department of Radiation Oncology (reference number for main clinical trial: MUMS/931296; reference number for this study: MUMS/930840). The ethical rules of research according to Helsinki Declaration were observed. Also, we were committed to keeping all of the participants' information confidential.

3. Results
==========

Tissue specimens of 43 patients with non-metastatic esophageal squamous cell carcinoma were selected. Patients' demographic information and tumor TNM status are summarized in [Table 1](#t1-epj-09-3756){ref-type="table"}. The median follow-up time was 32 months (range: 32--83), of which in 18 (43.9%) death occurred, while the median disease free survival time was 27 months (95% CI: 21.11--34.56).

3.1. MAGE1 cytoplasmic and nuclear expression
---------------------------------------------

MAGE1 was expressed in 46.5% (20 out of 43) of esophageal SCC specimens, overall. MAGE1 cytoplasmic and nuclear expression was detected in 34.9% (15 out of 43) and 30.2% (13 out of 43) of specimens, respectively ([Figure 2](#f2-epj-09-3756){ref-type="fig"}).

3.2. Association between MAGE1 cytoplasmic/nuclear expression and different clinicopathological parameters
----------------------------------------------------------------------------------------------------------

MAGE1 nuclear staining increased significantly by age (Person's R value= 0.3 and p=0.04). There was no significant correlation between MAGE1 cytoplasmic/nuclear expression and gender, tumor stage, lymph node status, tumor grade, disease free survival, outcome, and pathologic complete response (pCR). Associations between MAGE1 expression and clinicopathological variables are presented in [Tables 2](#t2-epj-09-3756){ref-type="table"} and [3](#t3-epj-09-3756){ref-type="table"}.

4. Discussion
=============

In this cross-sectional study, we determined the prevalence and pattern of MAGE1 expression in esophageal SCC and its clinicopathological significance in Iran as a high incidence area for esophageal cancers. The prevalence of cytoplasmic and nuclear MAGE1 expression was 34.9% and 30.2%, respectively, with a high variability in intensity and homogeneity. There was a significant and positive correlation between MAGE1 nuclear expression and age. Cancer/testis antigens exist normally in the testis tissue; they are protected by blood-testis barrier from the immune system. Cancer/testis antigens in the malignant cells, and peptides derived from them, can stimulate immune response, resulting in endogenous death of tumoral cells expressing these antigens ([@b23-epj-09-3756]--[@b25-epj-09-3756]). Thus, they have two unique features; 1) their confined expression in the tumoral and testicular cells 2) their immunogenic nature. These features make them potential targets for immunotherapy, and, chemoradiotherapy-induced immunogenic cell death ([@b26-epj-09-3756]--[@b28-epj-09-3756]). Previous studies have shown a considerable prevalence of MAGE1 expression in esophageal SCC, as did our study. A 2005 study by Liang et al measured the MAGE1 gene expression via RT-PCR and reported the gene overexpression in 25.7% of esophageal SCCs ([@b20-epj-09-3756]). The prevalence of MAGE1 in studies by Haier et al in 2006 and Chen et al in 2014 was 50% and 57% respectively ([@b18-epj-09-3756], [@b19-epj-09-3756]). Immunohistochemistry technique was used in these studies, similar to ours ([@b18-epj-09-3756], [@b19-epj-09-3756]). A 2011 study by Forghanifard et al showed that MAGE1 mRNA was overexpressed in 90.2% of esophageal SCC specimens in the Iranian population ([@b29-epj-09-3756]). MAGE1 antigen has a considerable expression in the Iranian esophageal SCC patients which is independent of gender, local invasion (T and N stages) and differentiation (grade). To the best of our knowledge, this study is among the first studies to determine the prevalence and pattern of MAGE1 expression in esophageal SCC and its clinicopathological significance in Iran. All together, these data demonstrate the importance of cancer/testis antigens, especially MAGE1 in esophageal SCC, and leading to its use as a potential target for immunotherapy as well as a diagnostic tool. Furthermore, immunohistochemistry, a simple and widely available method for examination of specimens, was applied. Although in other studies the correlation between age and expression of MAGE1 has been seen to be inconsistent ([@b18-epj-09-3756], [@b30-epj-09-3756]), the results of this study showed a positive association between MAGE1 expression scores and older age. Given that the esophagectomy is a high risk surgery among the elderly, leading to suboptimal treatment, or even life threatening complications ([@b31-epj-09-3756]), MAGE1 might provide a potential treatment target for these patients. Some authors have suggested that the expression of MAGE1 antigens is associated with dedifferentiation in various tumor entities ([@b32-epj-09-3756]), although neither we nor other authors found this correlation to exist ([@b18-epj-09-3756], [@b30-epj-09-3756]). Also, like previous reports, no relationship between MAGE1 expression and TNM classification was found in our study ([@b18-epj-09-3756], [@b30-epj-09-3756]).

5. Conclusions
==============

The prevalence of cytoplasmic and nuclear MAGE1 expression was 34.9% and 30.2%, respectively, which can be seen as considerable. Furthermore, the MAGE1 nuclear staining prevalence increased significantly by age. As a practical implication, the MAGE1 antigen could be used as a target for immunotherapy in a large proportion of esophageal SCC patients who express this antigen. In addition, high levels of MAGE1 expression in the elderly, indicate a possible and distinguished clinical benefit of immunotherapy in this subgroup of patients who may be unable to tolerate the standard treatment modalities. We also suggest further prospective studies assessing the prognostic and predictive value of the MAGE1 expression--possibly in a multicenter design, with a special focus on elderly patients.
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###### 

Demographic and TNM status of patients.

  Variable              n (%)               
  --------------------- ------------------- -----------
  Gender                Female              21 (48.8)
  Male                  22 (51.2)           
  Age (years)           \<54                18 (41.9)
  55--64                11 (25.6)           
  \>65                  14 (32.6)           
  T stage               Carcinoma in situ   10 (23.3)
  T1                    4 (9.3)             
  T2                    12 (27.9)           
  T3                    17 (39.5)           
  N stage               N0                  34 (79.1)
  N positive            7 (16.3)            
  N/E                   2 (4.7)             
  M stage               M0                  43 (100)
  M1                    0 (0)               
  Grade                 1                   14 (32.6)
  2                     12 (27.9)           
  3                     17 (39.5)           
  Pathologic response   Unfavorable         18 (41.9)
  Favorable             25 (58.1)           

###### 

Association between MAGE1 cytoplasmic expression and different clinicopathological parameters.

  Clinicopathological Parameter   Cytoplasmic expression; n (%)                                                                 
  ------------------------------- ------------------------------- ------------ ------------ ----------- ----------- ----------- -----
  Gender                          Male                            22           13 (59.1%)   2 (9.1%)    2 (9.1%)    5 (22.7%)   0.2
  Female                          21                              15 (71.4%)   3 (14.3%)    2 (9.5%)    1 (4.8%)                
  Age (years)                     \<54                            18           13 (72.2%)   2 (11.1%)   0 (0%)      3 (16.7%)   0.7
  55--64                          11                              6 (54.5%)    1 (9.1%)     3 (27.3%)   1 (9.1%)                
  \>65                            14                              9 (64.3%)    2 (14.3%)    1 (7.1%)    2 (14.3%)               
  Tumor stage                     T in                            10           7 (70%)      1 (10%)     1 (10%)     1 (10%)     0.1
  T1                              4                               4 (100%)     0 (0%)       0 (0%)      0 (0%)                  
  T2                              12                              9 (75%)      1 (8.40%)    2 (16.6%)   0 (0%)                  
  T3                              17                              8 (47%)      3 (17.6%)    1 (6%)      5 (29.4%)               
  Lymph node status               N0                              34           23 (67.6%)   3 (8.8%)    3 (8.8%)    5 (14.8%)   0.8
  N positive                      7                               4 (57.2%)    2 (28.6%)    0 (0%)      1 (14.2%)               
  N/E                             2                               1 (50%)      0 (0%)       1 (50%)     0 (0%)                  
  Tumor grade                     I                               14           11 (78.7%)   1 (7.1%)    1 (7.1%)    1 (7.1%)    0.1
  II                              12                              9 (75%)      1 (8.3%)     2 (16.7%)   0 (0%)                  
  III                             17                              8 (50%)      3 (0%)       1 (0%)      5 (50%)                 
  PCR                             Unfavorable                     18           9 (50%)      4 (22.2%)   1 (5.6%)    4 (22.2%)   0.1
  Favorable                       25                              19 (76%)     1 (4%)       3 (12%)     2 (8%)                  
  Disease free survival (month)   \<12                            13           9 (69.2%)    1 (7.7%)    0 (0%)      3 (23.1%)   0.4
  12--24                          9                               7 (77.8%)    2 (22.2%)    0 (0%)      0 (0%)                  
  \>24                            18                              10 (55.6%)   2 (11.1%)    4 (22.2%)   2 (11.1%)               
  Outcome                         Death                           18           12 (66.7%)   3 (16.7%)   1 (5.6%)    2 (11.1%)   0.8
  Alive                           23                              15 (65.2%)   2 (8.7%)     3 (13%)     3 (13%)                 

###### 

Association between MAGE1 nuclear expression and different clinicopathological parameters.

  Clinicopathological Parameter   Nuclear expression; n (%)                                                                 
  ------------------------------- --------------------------- ------------ ------------ ----------- ----------- ----------- --------
  Gender                          Male                        22           16 (72.7%)   1 (4.5%)    1 (4.5%)    4 (18.2%)   0.7
  Female                          21                          14 (66.7%)   3 (14.3%)    0 (0%)      4 (19%)                 
  Age (years)                     \<54                        18           16 (88.9%)   1 (5.6%)    0 (0%)      1 (5.6%)    0.04\*
  55--64                          11                          6 (54.5%)    2 (18.2%)    0 (0%)      3 (27.3%)               
  \>65                            14                          8 (57.1%)    1 (7.1%)     1 (7.1%)    4 (28.6%)               
  Tumor stage                     T in                        10           7 (70%)      1 (10%)     1 (10%)     1 (10%)     0.2
  T1                              4                           3 (75%)      1 (25%)      0 (0%)      0 (0%)                  
  T2                              12                          8 (66.6%)    2 (16.7%)    0 (0%)      2 (16.7%)               
  T3                              17                          12 (70%)     0 (0%)       0 (0%)      5 (30%)                 
  Lymph node status               N0                          34           23 (67.7%)   4 (11.7%)   1 (2.9%)    6 (17.7%)   0.5
  N positive                      7                           6 (85.8%)    0 (0%)       0 (0%)      1 (14.2%)               
  N/E                             2                           1 (50%)      0 (0%)       0 (0%)      1 (50%)                 
  Tumor grade                     I                           14           10 (71.4%)   2 (14.2%)   1 (7.2%)    1 (7.2%)    0.1
  II                              12                          8 (66.6%)    2 (16.7%)    0 (0%)      2 (16.7%)               
  III                             17                          12 (70.6%)   0 (0%)       0 (0%)      5 (29.4%)               
  pCR                             Unfavorable                 18           13 (72.2%)   0 (0%)      0 (0%)      5 (27.8%)   0.9
  Favorable                       25                          17 (68%)     4 (16%)      1 (4%)      3 (12%)                 
  Disease free survival (month)   \<12                        13           10 (76.9%)   0 (0%)      0 (0%)      3 (23.1%)   0.6
  12--24                          9                           6 (66.7%)    1 (11.1%)    0 (0%)      2 (22.2%)               
  \>24                            18                          11 (61.1%)   3 (5.6%)     1 (22.2%)   3 (16.7%)               
  Outcome                         Death                       18           11 (61.1%)   2 (11.1%)   1 (5.6%)    4 (22.2%)   0.7
  Alive                           23                          17 (73.9%)   2 (8.7%)     0 (0%)      4 (17.4%)               
